Roivant Sciences (ROIV) Jefferies 2024 Global Healthcare Conference summary

Business and financial outlook

• $6 billion in cash following the TL1A program sale, providing strong capital for new opportunities.

• Actively pursuing mid to late-stage drug programs, with several economic discussions ongoing and announcements expected in the coming weeks or months.

• Focused on high-quality deals rather than volume, aiming for transformative assets with significant long-term value.

• Willing to invest in programs with strong proof of concept and meaningful clinical data, targeting large indications.

• Prioritizing areas with less competition or where a novel approach can differentiate, avoiding crowded me-too mechanisms.

Therapeutic area and pipeline strategy

• Therapeutic focus is flexible, with interest in late-stage assets across immunology, pulmonology, cardiometabolic, and rare diseases.

• Less emphasis on core oncology and obesity due to competitive dynamics.

• FcRn remains a foundational mechanism, with broad potential across multiple indications.

• Pipeline includes pivotal programs in MG, CIDP, and Graves’ disease, with creative clinical development strategies to differentiate from competitors.

• Sarcoidosis and NIU are key upcoming readouts, with sarcoidosis representing an open field and high unmet need.

Recent clinical and regulatory updates

• Positive FDA Type B meeting for IMVT-1402, clearing key hurdles for pivotal studies.

• Minor delay in MG study timelines, but patient enrollment and quality remain strong.

• CIDP study timeline extended to ensure robust dose-ranging data, addressing patient washout challenges.

• Brepocitinib showed superior efficacy in NIU compared to Humira, with Phase III planned.

• Namilumab in sarcoidosis is a unique late-stage asset with no direct competitors and significant patient need.